Cash figures as of 2025-12-31. Database snapshot: 2026-09-21.
Price history
Loading NBP daily closes…
Loading price history…
Pipeline assets
Givastomig
Stage not disclosed · Active
Target Claudin18.2 x 4-1BB
Status note Lead focus area. FDA orphan drug designation granted; clinical trials initiated in the US. All candidates described as in early clinical development; no phase, indication, or readout timing stated in excerpts.
VIS-101
Stage not disclosed · Active
Target VEGF-A / ANG-2
Status note Open FDA IND; named as a focus area. No target, indication, or phase stated in excerpts.
Ragistomig
Stage not disclosed · Active
Target PD-L1 / 4-1BB
Status note Open FDA IND. No target, indication, or phase stated in excerpts.
Uliledlimab
Stage not disclosed · Active
Target CD73
Status note Open FDA IND; clinical trials initiated in the US. No target, indication, or phase stated in excerpts.
Per-asset detail extracted from the 20-F filed 2026-04-07. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.